Evaluation of DHAD in Advanced Squamous Cell Carcinoma of the Head and Neck

Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adnoid cystic carcinoma of the head and neck.

DE Mattox;DD Von Hoff;SP Balcerzak Invest New Drugs 8:105-107

Possible mitoxantrone-induced amenorrhea.

Shenkenberg;DD Von Hoff;RL Stephens;JG Boutselis Cancer Treat Rep 70(8):659-661

Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.

DE Mattox;GM Clark;SP Balcerzak;RM O'Bryan;N Oishi;WJ Stuckey Invest New Drugs 2: 405-407

Southwest Oncology Group Phase II studies with Mitoxantrone in nonhematologic malignancies.

RL Stephens;DD Von Hoff;SA Taylor;WA Knight III;RB Livingston;FE Bull;J Cowan;RD Hilgers;CK Osborne;GA Gates;G Clark In: New Anticancer Drugs: Mitoxantrone and Bisantrene . M Rozencweig, et al, eds. New York: Raven Press, 125-30

Cardiotoxicity in patients treated with Mitoxantrone on Southwest Oncology Group Phase II protocols.

GM Clark;LK Tokaz;DD Von Hoff;LL Thoi;CA Coltman Jr Cancer Treat Symp 3:25-30

Southwest Oncology Group (SWOG) Phase II with mitoxantrone in non-hematologic malignancies.

RL Stephens;G Clark 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (October 15-17, 1981), #36